The classic CJC-1295 human paper evaluated a long-acting albumin-binding analog in healthy adults. Its sustained hormone profile is evidence for the DAC form studied—not for every product sold under a CJC-1295 name.
What the record shows
- The report combined two randomized, placebo-controlled, double-blind ascending-dose trials lasting 28 and 49 days.
- Mean GH rose 2- to 10-fold for at least 6 days; mean IGF-1 rose 1.5- to 3-fold for 9–11 days after one administration.
- Estimated half-life was 5.8–8.1 days, consistent with the albumin-binding design.
Study record
The prolonged profile came from a reactive drug-affinity-complex design that covalently associates with endogenous albumin. That structural feature is central to interpreting the pharmacokinetics.
Results in context
A follow-up pulsatility study in healthy men found that GH pulses persisted during continuous stimulation. It was a mechanistic endocrine study, not a body-composition or performance trial.
The early report stated that no serious adverse reactions were reported in those trials. Current FDA review nevertheless identifies limited clinical data and serious adverse-event reports, including increased heart rate and a systemic vasodilatory reaction.
FDA source scope: the FDA bulk-safety summary lists “CJC-1295” generically and does not resolve DAC versus without-DAC in that row. It should not be used alone as form-specific causality evidence.
What this study cannot answer
Short pharmacodynamic studies do not establish long-term benefit or safety.
The results cannot be transferred to “without DAC” material or an analytically unlinked lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Prolonged stimulation of GH and IGF-I secretion by CJC-1295Teichman SL, et al. J Clin Endocrinol Metab. 2006. PMID 16352683.
- Pulsatile GH secretion persists during CJC-1295 stimulationIonescu M, Frohman LA. J Clin Endocrinol Metab. 2006. PMID 17018654.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
